These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15930097)

  • 21. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Bilous RW
    J Hum Hypertens; 2004 Oct; 18(10):733-8. PubMed ID: 15116142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study.
    Ferrari P; Hess L; Pechere-Bertschi A; Muggli F; Burnier M
    J Hypertens; 2004 Jun; 22(6):1221-9. PubMed ID: 15167458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
    Holtkamp FA; de Zeeuw D; de Graeff PA; Laverman GD; Berl T; Remuzzi G; Packham D; Lewis JB; Parving HH; Lambers Heerspink HJ
    Eur Heart J; 2011 Jun; 32(12):1493-9. PubMed ID: 21421598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.
    Hunsicker LG; Atkins RC; Lewis JB; Braden G; de Crespigny PJ; DeFerrari G; Drury P; Locatelli F; Wiegmann TB; Lewis EJ;
    Kidney Int Suppl; 2004 Nov; (92):S99-101. PubMed ID: 15485429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
    Ravera M; Ratto E; Vettoretti S; Parodi D; Deferrari G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S48-52. PubMed ID: 15938034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
    Angulo E; Robles NR; Grois J; Barquero A; Pérez Miranda M
    An Med Interna; 2002 Nov; 19(11):571-5. PubMed ID: 12522893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Hypertension: Which Goal for Which Patient?
    Jarraya F
    Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
    Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
    Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; de Alvaro F;
    Nefrologia; 2004; 24(3):231-8. PubMed ID: 15283313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.
    Palmer AJ; Tucker DM; Valentine WJ; Roze S; Gabriel S; Cordonnier DJ
    Nephrol Dial Transplant; 2005 Jun; 20(6):1103-9. PubMed ID: 15855214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan.
    Ogihara T; Matsuoka H; Rakugi H
    Geriatr Gerontol Int; 2011 Oct; 11(4):414-21. PubMed ID: 21410854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
    Ruggenenti P; Remuzzi G
    Nat Clin Pract Nephrol; 2006 May; 2(5):250-1. PubMed ID: 16932436
    [No Abstract]   [Full Text] [Related]  

  • 39. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.